The trial included 2,542 patients ages 45 to 69 years who had type 2 diabetes with an HbA1c of 6.9% or higher and hypertension, dyslipidemia, or both, recruited at 81 sites in Japan.
The retrospective study involved nearly 2.8 million male veterans 65 to 99 years of age, 32.3% with diabetes, who received primary care at Veterans Health Administration medical centers from 2000 to 2010.
From 2000 to 2014, the age-standardized incidence of end-stage renal disease (ESRD) attributed to diabetes decreased from 260.2 to 173.9 per 100,000 diabetic population.
The summary describes ways in which the Veterans Affairs/Department of Defense (VA/DoD) guideline differs from recommendations from the American Diabetes Association, the American Geriatrics Society, and the American Association of Clinical Endocrinologists.
The overall prevalence of diabetes (diagnosed and confirmed undiagnosed) increased from 5.5% of the U.S. population in 1988 to 1994 to 10.8% in 2011 to 2014, according to data from the National Health and Nutrition Examination Survey (NHANES).
Self-monitoring of blood glucose did not improve HbA1c or QOL at 1 year in non-insulin-treated type 2 diabetes
The randomized controlled trial adds to the evidence about routine use of self-monitoring of blood glucose for all patients with type 2 diabetes, according to an ACP Journal Club commentary.
Review: In diabetes, intensive and standard glycemic control do not differ for end-stage kidney disease or death
The review suggests that treating diabetes with strict glycemic control does not reduce mortality or cardiovascular risk or slow progression of kidney disease, and the results question whether strict glycemic control for preventing any complications is warranted, ACP Journal Club authors wrote.
An award-winning guidebook helps patients learn about diet, exercise, blood glucose monitoring, the importance of foot exams, and management of insulin and other medicines.